Relevant bibliographies by topics / Prostate cancer screening / Journal articles

Journal articles on the topic 'Prostate cancer screening'

To see the other types of publications on this topic, follow the link: Prostate cancer screening.
Author: Grafiati
Published: 4 June 2021
Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Prostate cancer screening.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kurator, Kevin, and Ian Jenkins. "Prostate cancer screening." Cleveland Clinic Journal of Medicine 88, no. 5 (May 2021): 260.2–260. http://dx.doi.org/10.3949/ccjm.88c.05002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zhang, Sherry, and Ian Jenkins. "Prostate cancer screening." Cleveland Clinic Journal of Medicine 88, no. 5 (May 2021): 260.1–260. http://dx.doi.org/10.3949/ccjm.88c.05001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ackermann, R. J. "Prostate cancer screening." CA: A Cancer Journal for Clinicians 40, no. 3 (May 1, 1990): 190–92. http://dx.doi.org/10.3322/canjclin.40.3.190.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rodríguez-Carlin, Arquímedes, and Octavio Castillo. "Prostate cancer screening." Medwave 16, no. 06 (July 22, 2016): e6504-e6504. http://dx.doi.org/10.5867/medwave.2016.06.6504.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Roetzheim, Richard G., and Arthur H. Herold. "PROSTATE CANCER SCREENING." Primary Care: Clinics in Office Practice 19, no. 3 (September 1992): 637–49. http://dx.doi.org/10.1016/s0095-4543(21)00943-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Peate, Ian. "Screening: prostate cancer." British Journal of Nursing 31, no. 6 (March 24, 2022): 303. http://dx.doi.org/10.12968/bjon.2022.31.6.303.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Faigen, Mark. "Prostate cancer screening." Medical Journal of Australia 199, no. 9 (November 2013): 585. http://dx.doi.org/10.5694/mja13.10827.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hall, R. R., and F. Alexander. "Prostate cancer screening." Journal of the Royal Society of Medicine 91, no. 9 (September 1998): 507. http://dx.doi.org/10.1177/014107689809100929.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sikaris, Ken. "Prostate cancer screening." Pathology 44, no. 2 (February 2012): 99–109. http://dx.doi.org/10.1097/pat.0b013e32834fbb2c.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Catalona, William J. "Prostate cancer screening." BJU International 94, no. 7 (November 2004): 964–66. http://dx.doi.org/10.1111/j.1464-410x.2004.05187.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Catalona, William J. "Prostate Cancer Screening." Medical Clinics of North America 102, no. 2 (March 2018): 199–214. http://dx.doi.org/10.1016/j.mcna.2017.11.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Hill, M. J. "Prostate cancer screening." European Journal of Cancer Prevention 11, no. 3 (June 2002): 313–14. http://dx.doi.org/10.1097/00008469-200206000-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Finne, Patrik, Anssi Auvinen, and Ulf-Håkan Stenman. "Prostate cancer screening." Lancet 357, no. 9263 (April 2001): 1201. http://dx.doi.org/10.1016/s0140-6736(00)04340-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Ablin, Richard J. "Prostate cancer screening." Lancet 357, no. 9263 (April 2001): 1201. http://dx.doi.org/10.1016/s0140-6736(00)04341-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Wolk, Alicja, Fredrik Granath, Swen-Olof Andersson, Dimitrios Trichopoulos, and Hans-Olov Adami. "Prostate cancer screening." Lancet 357, no. 9263 (April 2001): 1201–2. http://dx.doi.org/10.1016/s0140-6736(00)04342-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Mannello, Ferdinando, and Giancarlo Gazzanelli. "Prostate cancer screening." Lancet 357, no. 9263 (April 2001): 1202. http://dx.doi.org/10.1016/s0140-6736(00)04343-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Stattin, Pår, Ulf-Håkan Stenman, Elio Riboli, Göran Hallmans, and Rudolf Kaaks. "Prostate cancer screening." Lancet 357, no. 9263 (April 2001): 1202–3. http://dx.doi.org/10.1016/s0140-6736(00)04344-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Dunn, Mary Weinstein. "Prostate Cancer Screening." Seminars in Oncology Nursing 33, no. 2 (May 2017): 156–64. http://dx.doi.org/10.1016/j.soncn.2017.02.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Ragsdale, John W., Brian Halstater, and Viviana Martinez-Bianchi. "Prostate Cancer Screening." Primary Care: Clinics in Office Practice 41, no. 2 (June 2014): 355–70. http://dx.doi.org/10.1016/j.pop.2014.02.009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Blackwelder, Russ, and Alexander Chessman. "Prostate Cancer Screening." Primary Care: Clinics in Office Practice 46, no. 1 (March 2019): 149–55. http://dx.doi.org/10.1016/j.pop.2018.10.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Holt, James D., and Fereshteh Gerayli. "Prostate Cancer Screening." Primary Care: Clinics in Office Practice 46, no. 2 (June 2019): 257–63. http://dx.doi.org/10.1016/j.pop.2019.02.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Godley, Paul A. "Prostate Cancer Screening." Annals of Internal Medicine 120, no. 12 (June 15, 1994): 1052. http://dx.doi.org/10.7326/0003-4819-120-12-199406150-00028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Meyers, Frederick J. "Prostate Cancer Screening." Annals of Internal Medicine 120, no. 12 (June 15, 1994): 1052. http://dx.doi.org/10.7326/0003-4819-120-12-199406150-00029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Kramer, Barnett S. "Prostate Cancer Screening." Annals of Internal Medicine 120, no. 12 (June 15, 1994): 1052. http://dx.doi.org/10.7326/0003-4819-120-12-199406150-00030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Walther, Philip J. "Prostate Cancer Screening." Surgical Oncology Clinics of North America 4, no. 2 (April 1995): 315–34. http://dx.doi.org/10.1016/s1055-3207(18)30457-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Hostetler, Russell M., Ira G. Mandel, and Jan Marshburn. "PROSTATE CANCER SCREENING." Medical Clinics of North America 80, no. 1 (January 1996): 83–98. http://dx.doi.org/10.1016/s0025-7125(05)70428-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Seltzer, Sharon. "Prostate cancer screening." Current Surgery 59, no. 5 (September 2002): 476. http://dx.doi.org/10.1016/s0149-7944(01)00635-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Carter, H. Ballentine. "Prostate cancer screening." Urology 59, no. 3 (March 2002): 464. http://dx.doi.org/10.1016/s0090-4295(01)01613-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Lewis, Ryan. "Prostate Cancer Screening." Physician Assistant Clinics 3, no. 1 (January 2018): 1–9. http://dx.doi.org/10.1016/j.cpha.2017.08.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Wilson, Shandra S. "Prostate cancer screening." Comprehensive Therapy 31, no. 2 (June 2005): 119–23. http://dx.doi.org/10.1007/s12019-005-0007-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

FEERO, GREG. "Prostate Cancer Screening." Family Practice News 39, no. 7 (April 2009): 29. http://dx.doi.org/10.1016/s0300-7073(09)70272-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Sandblom, Gabriel, and Eberhard Varenhorst. "Prostate cancer screening." Cancer Causes & Control 19, no. 10 (June 3, 2008): 1411. http://dx.doi.org/10.1007/s10552-008-9180-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Luckmann, Roger. "Prostate Cancer Screening." Annals of Internal Medicine 135, no. 11 (December 4, 2001): 1018. http://dx.doi.org/10.7326/0003-4819-135-11-200112040-00029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Eastham, James. "Prostate cancer screening." Investigative and Clinical Urology 58, no. 4 (2017): 217. http://dx.doi.org/10.4111/icu.2017.58.4.217.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Wilson, Shandra S. "Prostate Cancer Screening." Comprehensive Therapy 31, no. 2 (2005): 119–23. http://dx.doi.org/10.1385/comp:31:2:119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Thompson, I. M. "Prostate cancer screening." Archives of Family Medicine 4, no. 4 (April 1, 1995): 307–8. http://dx.doi.org/10.1001/archfami.4.4.307.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Calsoyas, Isis, and M. Suzanne Stratton. "Prostate Cancer Screening." Archives of Internal Medicine 164, no. 17 (September 27, 2004): 1830. http://dx.doi.org/10.1001/archinte.164.17.1830.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Atkins, D. "Prostate cancer screening." JAMA: The Journal of the American Medical Association 277, no. 4 (January 22, 1997): 299b—300. http://dx.doi.org/10.1001/jama.277.4.299b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Cook, Elise D., and Ana C. Nelson. "Prostate Cancer Screening." Current Oncology Reports 13, no. 1 (October 28, 2010): 57–62. http://dx.doi.org/10.1007/s11912-010-0136-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Ho, Reginald C. S. "Prostate cancer screening." Journal of Surgical Oncology 56, no. 2 (June 1994): 69–70. http://dx.doi.org/10.1002/jso.2930560203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Kuehn, Bridget M. "Prostate Cancer Screening." JAMA 300, no. 12 (September 24, 2008): 1403. http://dx.doi.org/10.1001/jama.300.12.1403-d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Alexander, Freda E. "Prostate cancer screening." Microscopy Research and Technique 51, no. 5 (2000): 419–22. http://dx.doi.org/10.1002/1097-0029(20001201)51:5<419::aid-jemt3>3.0.co;2-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Razmaria, Aria A. "Prostate Cancer Screening." JAMA 314, no. 19 (November 17, 2015): 2096. http://dx.doi.org/10.1001/jama.2015.15295.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Eggener, Scott E., Adam S. Cifu, and Chadi Nabhan. "Prostate Cancer Screening." JAMA 314, no. 8 (August 25, 2015): 825. http://dx.doi.org/10.1001/jama.2015.8033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Atkins, David. "Prostate Cancer Screening." JAMA: The Journal of the American Medical Association 277, no. 4 (January 22, 1997): 299. http://dx.doi.org/10.1001/jama.1997.03540280037029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Reungwetwattana, Thanyanan, Julian R. Molina, and Jeanette Y. Ziegenfuss. "Factors and trends in cancer screening in the United States from 2004 to 2010." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 1565. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.1565.

Full text
Abstract:
1565 Background: Understanding the prevalence of cancer screening in the US and the factors associated with its accessibility is important for public health promotion. Methods: The 2004 and 2010 Behavioral Risk Factor Surveillance Systems were used to ascertain cancer screening rates among populations indicated for each test by age, gender, and the American Cancer Society recommendation for cancer screenings [fecal occult blood test (FOBT) or endoscopy for colorectal cancer (CRC) screening, digital rectal examination (DRE) or prostate specific antigen (PSA) for prostate cancer screening, clinical breast examination (CBE) or mammogram for breast cancer screening, and Papanicolaou (Pap) test for cervical cancer screening]. Results: Over this period, CRC and breast cancer screening rates significantly increased (15.9%, 13.9%) while prostate and cervical cancer screening rates significantly decreased (1.2%, 5.2%). Race/ethnicity might be an influence in CRC and cervical cancer screening accessibility. Prostate cancer screening accessibility might be influenced by education and income. The older-aged populations (70-79, >79) had high prevalence of CRC, prostate and breast cancer screenings even though there is insufficient evidence for the benefits and harms of screenings in the older-aged group. Conclusions: The disparities in age, race/ethnicity, health insurance, education, employment, and income for the accession to cancer screening of the US population have decreased since 2004. The trajectory of increasing rates of CRC and breast cancer screenings should be maintained. To reverse the trend, the causes of the decreased rate of cervical cancer screening and the high rates of screenings in older-aged populations should, however, be further explored. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
47

Brawley, Otis W., Ian M. Thompson, and Henrik Grönberg. "Evolving Recommendations on Prostate Cancer Screening." American Society of Clinical Oncology Educational Book, no. 36 (May 2016): e80-e87. http://dx.doi.org/10.1200/edbk_157413.

Full text
Abstract:
Results of a number of studies demonstrate that the serum prostate-specific antigen (PSA) in and of itself is an inadequate screening test. Today, one of the most pressing questions in prostate cancer medicine is how can screening be honed to identify those who have life-threatening disease and need aggressive treatment. A number of efforts are underway. One such effort is the assessment of men in the landmark Prostate Cancer Prevention Trial that has led to a prostate cancer risk calculator (PCPTRC), which is available online. PCPTRC version 2.0 predicts the probability of the diagnosis of no cancer, low-grade cancer, or high-grade cancer when variables such as PSA, age, race, family history, and physical findings are input. Modern biomarker development promises to provide tests with fewer false positives and improved ability to find high-grade cancers. Stockholm III (STHLM3) is a prospective, population-based, paired, screen-positive, prostate cancer diagnostic study assessing a combination of plasma protein biomarkers along with age, family history, previous biopsy, and prostate examination for prediction of prostate cancer. Multiparametric MRI incorporates anatomic and functional imaging to better characterize and predict future behavior of tumors within the prostate. After diagnosis of cancer, several genomic tests promise to better distinguish the cancers that need treatment versus those that need observation. Although the new technologies are promising, there is an urgent need for evaluation of these new tests in high-quality, large population-based studies. Until these technologies are proven, most professional organizations have evolved to a recommendation of informed or shared decision making in which there is a discussion between the doctor and patient.
APA, Harvard, Vancouver, ISO, and other styles
48

Snyder, Claire, Peggy N. Schrammel, Claudia B. Griffiths, and Robert I. Griffiths. "Prostate Cancer Screening in the Workplace." AAOHN Journal 46, no. 8 (August 1998): 379–84. http://dx.doi.org/10.1177/216507999804600803.

Full text
Abstract:
Recognition of the mortality and morbidity associated with prostate cancer has resulted in employer based screening programs. This retrospective cohort study identified the employer costs of prostate cancer screening and referrals due to abnormal test results. The subjects were 385 men enrolled in a workplace screening program at a single employer between 1993 and 1995. Screening consisted of digital rectal examination (DRE) annually for enrolled employees aged 40 years and older, plus annual prostate specific antigen (PSA) testing for those 50 and older, and those 40 and older and considered at high risk. Data related to the health care and lost productivity costs of screening and referrals for abnormal test results were collected and analyzed. The total cost of screening was $44,355, or approximately $56 per screening encounter (788 DREs; 437 PSAs). Abnormal screening tests resulted in 52 referrals. Upon further evaluation, 42% were found to have an enlargement, 29% a node, and 12% benign prostatic hyperplasia. Only one malignancy was found. The total cost of additional referrals was $31,815, or 42% of the cost of screening plus referrals. As the cost per screening encounter was low, prostate cancer screening in the workplace is an efficient alternative.
APA, Harvard, Vancouver, ISO, and other styles
49

Okidi, Ronald, Cyprian Opira, Vanusa Da Consolação Sambo, Caroline Achola, and David Martin Ogwang. "Prostate hyperplasia in St Mary’s Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancy." African Health Sciences 20, no. 3 (October 7, 2020): 1259–63. http://dx.doi.org/10.4314/ahs.v20i3.30.

Full text
Abstract:
Introduction: Prostate cancer is the second commonest cancer in men worldwide. At present, every patient with lower urinary tract symptoms (LUTS) in St. Mary’s Hospital Lacor is undergoing prostate biopsy regardless of the prostate specific antigen (PSA) level. We sought to determine the association between PSA and malignant prostate histology. Methods: This was a retrospective study. Data on age, PSA, prostate volume and prostate histology reported between Jan 2012 and Dec 2019 were retrieved from St. Mary’s Hospital Lacor archive and analyzed using STATA SE/13.0. Results: Records of 97 patients with LUTS was analyzed. The median (range) age of the patients was 71 (43-100) years. Median (range) of prostate volume was 91.8 (8.0-360.0) cc. Overall, PSA ranged from 0.21 to 399.2 ng/ml. Prostate histology showed 3.1% acinar adenocarcinoma, 24.7% adenocarcinoma and 72.2% benign prostatic hyperplasia. The median PSA amongst pa- tients with malignant and non-malignant prostates were 15.8 ng/ml and 6.07 ng/ml respectively. Serum PSA level was signifi- cantly higher in patients with malignant prostate histology (Difference of mean= 9.7; p=0.001). Conclusion: Patients with LUTS and PSA levels of 15ng/ml or more were more likely to have malignant prostate histology. Keywords: Prostate specific antigen; Prostate cancer.
APA, Harvard, Vancouver, ISO, and other styles
50

Ford, Marvella E., Suzanne L. Havstad, Ray Demers, and Christine Cole Johnson. "Effects of False-Positive Prostate Cancer Screening Results on Subsequent Prostate Cancer Screening Behavior." Cancer Epidemiology, Biomarkers & Prevention 14, no. 1 (January 1, 2005): 190–94. http://dx.doi.org/10.1158/1055-9965.190.14.1.

Full text
Abstract:
Abstract Objectives: Little is known about screening behavior following a false-positive prostate cancer screening result, which we have defined as a screening result with “abnormal/suspicious” labeling that did not result in a prostate cancer diagnosis within 14 months. The purpose of this analysis was to examine whether age, race, education, or previous false-positive prostate cancer screening results via prostate-specific antigen or digital rectal exam predict decision to obtain subsequent prostate cancer screening. Methods: Data were drawn from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. The study sample consisted of 2,290 older men (mean age, 62.8 years; range, 55-75 years) who had false-positive (n = 318) or negative (n = 1,972) prostate-specific antigen or digital rectal exam baseline prostate cancer screening results. Multivariable logistic regression was used to assess the effect of false-positive results on subsequent prostate cancer screening behavior, adjusting for all covariates. Results: The multivariable model showed that being African American (P = 0.016), and having a high school education or less (P = 0.007), having a previous false-positive prostate cancer screening result (P &lt; 0.001), were predictive of not returning for prostate cancer screening in the following screening trial year. Conclusion: The study results highlight the importance of shared decision making between patients and their providers regarding the risks and benefits of prostate cancer screening, and follow-up options for abnormal prostate cancer screening results. Shared decision making may be especially important for African American men, whom prostate cancer disproportionately affects.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Prostate cancer screening' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography